Anastrozol 1mg

Anastrozole 1 mg

Brand: Magnus Pharmaceuticals
Content: 30 tablets | 1 mg per tablet
Price: €35
Manufactured in: Europe

🧪 Product Overview

Anastrozole 1 mg is a third-generation non-steroidal aromatase inhibitor (AI) designed to suppress peripheral estrogen synthesis via competitive inhibition of the CYP19 enzyme. Widely used in endocrine and oncology research, it allows for precise estrogen-reduction modeling, testosterone-to-estradiol (T:E) modulation, and post-cycle therapy simulations.

Its long half-life (~46–50 hours) supports once-daily dosing, and the film-coated tablets offer logistical advantages over injectables in hormone-regulation studies. With high selectivity and oral bioavailability, anastrozole is a key tool in studies of male hypogonadism, fertility, and body recomposition protocols.

✅ Key Research Highlights

Selective aromatase blockade:
Inhibits CYP19 to suppress peripheral estrogen by ≥80% in vivo [DrugBank, NCBI]

Extended half-life:
Elimination t½ ≈ 46–50 hours supports consistent once-daily sampling [PubChem, Wikipedia]

T:E ratio modulation:
1 mg/day improved testosterone-to-estradiol ratios and semen metrics in male trials [PMC]

Body recomposition support:
Reduced systemic estrogen helps prevent gynecomastia and sustain lean-mass retention [Verywell Health]

Room-temperature stability:
Film-coated tablets store safely ≤25 °C — no cold-chain required [Mayo Clinic]

🧬 Suggested Laboratory Applications

Aromatase inhibition and estrogen-suppression studies

Post-cycle therapy and hormonal recovery research

T:E ratio modulation in hypogonadal or fertility trials

Anti-estrogen support in anabolic-steroid modeling

Oncology research in estrogen-dependent tumors

📊 Technical Specifications

Field	Data
Chemical Name	Anastrozole
Chemical Formula	C17H19N5
Synonyms	Arimidex, ICI D1033, CP-65787, α,α,α′-Tris(1H-1,2,4-triazol-1-yl-m-tolyloxy)-m-xylene
Molecular Weight	293.37 g/mol
CAS Number	120511-73-1
Half-life	46–50 hours
Detection Window	Medium-to-long (varies with dose and sampling)
Documented Benefits	↓ estrogen >80%, ↑ T:E ratio, ↓ recurrence of ER+ breast cancer
Main Risks	Arthralgia, hot-flushes, lipid shifts, bone-density reduction
Total Active Compound	30 mg per carton (1 mg × 30 tablets)
Shelf-life	36 months (manufacturer specification)

❄️ PubChem-Supported Research Insights

Suppresses peripheral estrogen synthesis by over 80%

Increases T:E ratio in hypogonadal males and fertility models

Demonstrated efficacy in reducing recurrence of estrogen-dependent cancers

Supports lean tissue retention and gynecomastia control

Extended half-life allows single daily dosing for consistent hormonal regulation

⚠️ Documented Research Side Effects

Joint pain, bone mineral density reduction, hot-flushes

Altered lipid profiles (↓ HDL, ↑ LDL) in chronic use

Cardiovascular strain risk with long-term administration

Insomnia and mood shifts in estrogen-sensitive models

🧯 Handling & Compliance

For Research Use Only — Not for human or veterinary use
Store at 15–25 °C, protect from moisture and light
Purchase confirms qualified researcher status
Listed on WADA Prohibited List S4 — any exposure may result in a positive anti-doping test